- •In this cohort, 5.4% of asymptomatic BRCA mutation carriers had occult carcinomas in risk-reducing surgery specimens.
- •Patients with STIC had a higher incidence of subsequent serous cancer than those with benign adnexa.
- •The optimal postoperative management of patients with occult STIC lesions is unknown.
To report the frequency and features of occult carcinomas and the incidence of subsequent cancers following risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers.
257 consecutive women with germline BRCA mutations who underwent RRSO between January 1, 2000 and December 31, 2014 were identified in an Institutional Review Board approved study. All patients were asymptomatic with normal physical exams, CA 125 values, and imaging studies preoperatively, and had at least 12 months of follow-up post-RRSO. All patients had comprehensive adnexal sectioning performed. Patient demographics and clinico-pathologic characteristics were extracted from medical and pathology records.
The cohort included 148 BRCA1, 98 BRCA2, 6 BRCA not otherwise specified (NOS), and 5 BRCA1 and 2 mutation carriers. Occult carcinoma was seen in 14/257 (5.4%) of patients: 9 serous tubal intraepithelial carcinomas (STIC), 3 tubal cancers, 1 ovarian cancer, and 1 endometrial cancer. Three patients (1.2%) with negative pathology at RRSO subsequently developed primary peritoneal serous carcinoma (PPSC), and 2 of 9 patients (22%) with STIC subsequently developed pelvic serous carcinoma. 110 women (43%) were diagnosed with breast cancer prior to RRSO, and 14 of the remaining 147 (9.5%) developed breast cancer following RRSO. Median follow-up of the cohort was 63 months.
In this cohort, 5.4% of asymptomatic BRCA mutation carriers had occult carcinomas at RRSO, 86% of which were tubal in origin. The risk of subsequent PPSC for women with benign adnexa at RRSO is low; however, the risk of pelvic serous carcinoma among women with STIC is significantly higher.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Genetics and biology of gynecologic cancers.in: Karlan B.Y. Bristow R.E. Li A.J. Gynecologic Oncology: Clinical Practice & Surgical Atlas. 1st ed. McGraw-Hill, China2012
- Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.Arch. Gynecol. Obstet. 2011; 283: 623-627
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.Am. J. Hum. Genet. 2003; 72: 1117-1130
- Ovarian cancer screening in women with a family history of breast or ovarian cancer.Obstet. Gynecol. 2006; 108: 1176-1184
- No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.Br. J. Cancer. 2007; 96: 1335-1342
- Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.N. Engl. J. Med. 2002; 346: 1609-1615
- Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.Lancet Oncol. 2006; 7: 223-229
- Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.Int. J. Gynecol. Cancer. 2011; 21: 846-851
- Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.Breast Cancer Res. Treat. 2010; 124: 195-203
- Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.Gynecol. Oncol. 2006; 100: 58-64
- Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.Gynecol. Oncol. 2014; 132: 280-286
- Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.Gynecol. Oncol. 2012; 127: 88-93
- Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.BJOG. 2011; 118: 814-824
- Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.J. Clin. Oncol. 2005; 23: 127-132
- Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.Am. J. Surg. Pathol. 2009; 33: 1878-1885
- Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the “sectioning and extensively examining the FIMbriated end” (SEE-FIM) protocol?.Int. J. Gynecol. Pathol. 2013; 32: 353-357
- Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families.Lancet. 1982; 2: 795-797
- Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry.Cancer. 1993; 71: 2751-2755
- Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review.Gynecol. Oncol. 2015; 139: 568-572
- Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.JAMA. 2006; 296: 185-192
- Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.Gynecol. Oncol. 2014; 132: 261-263
- The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.Am. J. Surg. Pathol. 2006; 30: 230-236
- Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann. Surg. 2004; 240: 205-213
- Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.Am. J. Obstet. Gynecol. 2006; 194: 1702-1709
- Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.Eur. J. Cancer. 2013; 49: 132-141
- Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.Gynecol. Oncol. 2010; 118: 295-298
- Microscopic and early-stage ovarian cancers in BRCA 1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.Cancer Prev. Res. (Phila.). 2011; 4: 463-470
- Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.Gynecol. Oncol. 2013; 129: 364-371
- Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.Neoplasia. 2011; 13: 899-911
- Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers.Gynecol. Oncol. 2011; 122: 339-343
- Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.Gynecol. Oncol. 2009; 75: 300-304
- Narod SA; hereditary ovarian cancer clinical study group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.Gynecol. Oncol. 2007; 104: 7-10
- High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.Eur. J. Surg. Oncol. 2006; 32: 1097-1100
- BRCA germline mutations in women with uterine serous carcinoma–still a debate.Int. J. Gynecol. Cancer. 2010; 20: 1531-1534
- Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?.Gynecol. Oncol. 2000; 79: 477-481
- Risk of endometrial carcinoma associated with BRCA mutation.Gynecol. Oncol. 2001; 80: 395-398
- The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.Gynecol. Oncol. 2013; 130: 127-131
Published online: September 09, 2016
Accepted: August 31, 2016
Received in revised form: August 24, 2016
Received: July 28, 2016
© 2016 Published by Elsevier Inc.